EQUITY |
9 Months Ended |
|---|---|
Jan. 31, 2026 | |
| EQUITY | |
| EQUITY | NOTE – 8: EQUITY
Common Stock
On April 26, 2022, the Company filed an amendment to the Articles of Incorporation increasing the authorized shares of common stock to 600,000,000 with a par value of $0.0001 and the total number of preferred shares at 20,000,000, par value $0.0001.
During the nine months ending January 31, 2025 the Company issued 10,686,860 shares of common stock for the conversion of 1,068,686 of Series B preferred shares.
During the nine months ending January 31, 2025 the Company issued 850,000 shares of common stock with a value of $55,000 for the payment of consulting fees.
During the nine months ending January 31, 2025 the Company issued 1,631,143 shares of common stock for the conversion of 26 shares of series D preferred shares.
During nine months ended January 31, 2025, the Company issued 1,250,000 shares of common stock with a value of $62,500 for the conversion of convertible debt.
During the nine months ending January 31, 2025 the Company issued 10,000,000 shares with an aggregate value of $695,000 for the payment of related party debt. As part of the conversion the Company recognized a loss on notes of $295,000.
During the nine months period ended January 31, 2026, the Company issued 3,383,876 shares of common stock with a value of $33,839 for the conversion of 29 preferred D shares.
Preferred Stock
The Company has 20,000,000 shares of $0.0001 par value preferred stock authorized and has designated a Series A preferred stock, a Series B preferred stock, a series C preferred stock and a series D preferred stock. The Company has authorized 5,000,000 series A and B shares each plus 1,500,000 each of series C and D preferred shares Each share of the Series A preferred stock is convertible into ten common shares and carries voting rights on the basis of 100 votes per share. Each share of the Series B preferred stock is convertible into ten common shares and carries no voting rights. Each of the Series C preferred shares are non-voting and are convertible to common stock as a “Blank Check” designation with terms and conditions as set by the board of directors. Each of the series D preferred shares are non-voting and may be converted into common shares as a Blank Check” designation with the terms and conditions as set forth by the board of directors
On April 26, 2022, the Company filed an amendment to the Articles of Incorporation increasing the authorized shares of common stock to 600,000,000 with a par value of $0.0001 and the total number of preferred shares at 20,000,000, par value $0.0001.
During the nine months ending January 31, 2025 the Company issued 10,686,860 shares of common stock for the conversion of 1,068,686 of Series B preferred shares.
During the nine months ending January 31, 2025 the Company issued 1,631,143 shares of common stock for the conversion of 26 shares of series D preferred shares.
During the nine months ending January 31, 2025 the Company issued 213,314 shares of series B preferred shares to settle $843,831 for accrued payables. The result of this issuance was a gain on debt of approximately $723,065.
During the nine months ending January 31, 2025 the Company issued 94,991 shares of series B for settling $367,431 of accrued payables due to 2 related parties.
During the nine months period ended January 31, 2026, the Company issued 3,383,876 shares of common stock with a value of $33,839 for the conversion of 29 preferred D shares.
As of January 31, 2026, the Company has 3,735,920 shares of preferred stock consisting of; 2,535,135 Series A shares, 1,200,254 Series B shares and 531 Series D preferred share issued and outstanding. The conversion price for the 531 series D shares issued is $0.50 or 80% of the lowest trading price 20 days prior to conversion, |